• Cyclic di-GMP (SKU B7839): Reliable Solutions for Lab Biofil

  2026-05-26

  This article delivers scenario-driven, evidence-backed guidance for biomedical researchers and lab professionals using Cyclic di-GMP (SKU B7839) in biofilm and immune modulation studies. Drawing on current literature and the APExBIO product dossier, it addresses practical challenges in protocol optimization, data interpretation, and product selection—supporting reproducibility and translational impact.

• Gramine in Triple-Negative Breast Cancer: Molecular Mechanis

  2026-05-25

  Explore how Gramine, a potent ferroptosis inducer, advances triple-negative breast cancer research by modulating CUL3-mediated ubiquitination of MTDH. This article delivers in-depth mechanistic insights, practical assay recommendations, and a unique translational perspective for cancer biology investigators.

• nor-Binaltorphimine Dihydrochloride: Circuit-Specific Insigh

  2026-05-25

  Explore the advanced application of nor-Binaltorphimine dihydrochloride as a selective κ-opioid receptor antagonist. This article reveals how circuit-level discoveries are shaping pain modulation research and practical assay design.

• Sulfaphenazole: Selective CYP2C9 Inhibitor for Vascular and

  2026-05-24

  Sulfaphenazole is a highly selective CYP2C9 inhibitor with proven efficacy in vascular endothelial function research and antibacterial studies. Its unique ability to inhibit cytochrome P450 2C9 and 2C6, while exhibiting low cytotoxicity, enables broad translational applications. APExBIO’s Sulfaphenazole (C4131) is widely utilized in drug metabolism modulation and wound healing models.

• Adefovir (GS-0393): Advanced Antiviral Mechanisms and Transl

  2026-05-23

  Explore how Adefovir (GS-0393) serves as a precision HBV antiviral agent, with a deep dive into its DNA polymerase inhibition pathway, renal transporter profiling, and practical considerations for hepatitis B virus research. This article offers new translational perspectives and protocol clarity beyond standard reviews.

• SOX9 and MAML2 Mediate β-Catenin Turnover Independently of G

  2026-05-22

  Sinha et al. reveal a novel pathway for repressing Wnt/β-catenin signaling, showing that SOX9 induces MAML2 to promote β-catenin degradation independently of the canonical destruction complex and proteasome. This finding refines our understanding of signaling regulation in development and stem cell biology, with implications for stem cell fate and disease modeling.

• Phos binding reagent (Phosbind) acrylamide in SDS-PAGE Workf

  2026-05-22

  Phos binding reagent (Phosbind) acrylamide enables direct, antibody-free differentiation of phosphorylated and non-phosphorylated proteins during SDS-PAGE, streamlining protein phosphorylation analysis. This tool is suitable for resolving phosphorylation states in proteins ranging from 30–130 kDa, but is not optimized for detection outside this molecular weight range or in workflows requiring long-term stock solutions.

• Salinomycin in HCC Research: Mechanistic Insight to Applicat

  2026-05-21

  This thought-leadership article explores Salinomycin—a polyether ionophore antibiotic with powerful anti-cancer properties—as a transformative tool in hepatocellular carcinoma (HCC) research. By integrating mechanistic evidence, strategic protocol guidance, and lessons from recent methodological advances, it provides translational researchers with a roadmap for leveraging Salinomycin across experimental and preclinical workflows. The discussion is anchored in current literature and highlights the superior utility of APExBIO’s Salinomycin for rigorous, reproducible studies.

• (-)-Norepinephrine (+)-bitartrate in Cardiovascular Models

  2026-05-21

  (-)-Norepinephrine (+)-bitartrate is a gold-standard tool for adrenergic signaling and cardiomyopathy workflows, offering precision and reproducibility as a potent vasoconstrictor. This guide translates reference-backed findings into actionable protocols, troubleshooting insights, and advanced research applications for cardiovascular and metabolic pathway studies.

• BRD4770 and G9a Inhibition: Shaping the Next Era in Cancer E

  2026-05-20

  BRD4770, a G9a histone methyltransferase inhibitor, is redefining the boundaries of epigenetic research in cancer biology. This article provides a mechanistic deep dive into G9a’s role in oncogenesis, discusses experimental validation of BRD4770 (notably in PANC-1 models), sets the competitive landscape in the context of recent co-targeting strategies, and offers actionable guidance for translational researchers. By integrating recent evidence on the c-MYC-G9a-FTH1 axis and highlighting APExBIO’s rigorous product validation, we outline how advanced epigenetic probes like BRD4770 can fuel innovation beyond conventional product guides.

• Tamsulosin (C6445): Data-Driven Solutions for Laboratory Uro

  2026-05-20

  This article explores real-world laboratory challenges in cell viability, smooth muscle, and urological disease research, demonstrating how Tamsulosin (SKU C6445) offers reproducibility, robust solubility in DMSO, and clinically validated efficacy. Grounded in quantitative data and best practices, this piece provides actionable, scenario-based guidance for biomedical researchers seeking reliable outcomes.

• Adefovir (GS-0393): Advanced Protocols for HBV Antiviral Res

  2026-05-19

  Adefovir (GS-0393) is a gold-standard nucleotide analog for hepatitis B virus research, uniquely enabling both robust DNA polymerase inhibition and renal transporter phenotyping. This guide delivers actionable protocols, troubleshooting insights, and workflow enhancements for maximizing experimental reproducibility using APExBIO’s high-purity Adefovir.

• Fluorinated CXCR4 Inhibitor A1 Advances Colorectal Cancer Th

  2026-05-19

  Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, demonstrating superior efficacy over AMD3100 in inhibiting tumor growth and modulating the tumor microenvironment in colorectal cancer models. Their comprehensive approach highlights the promise of targeted CXCL12/CXCR4 axis disruption for cancer metastasis inhibition and immune modulation.

• Strategic EZH2 Inhibition: EPZ-6438 in Translational Oncolog

  2026-05-18

  This thought-leadership article unpacks the mechanistic, experimental, and translational dimensions of EPZ-6438, a highly selective EZH2 inhibitor, providing actionable guidance for researchers seeking to disrupt PRC2-mediated oncogenic silencing. Leveraging recent evidence and workflow insights, we delineate the compound’s role in epigenetic cancer research, competitive positioning, and future directions for combinatorial therapy strategies.

• Translating κ-Opioid Antagonism: Mechanisms, Circuits, and S

  2026-05-18

  This thought-leadership article explores the strategic deployment of nor-Binaltorphimine dihydrochloride—a potent, selective κ-opioid receptor antagonist—in translational pain research. We synthesize recent mechanistic discoveries on brain-to-spinal circuits that govern mechanical allodynia, integrate best practices for experimental design, and position APExBIO’s offering within the competitive reagent landscape. The discussion bridges foundational opioid receptor signaling research with actionable guidance for next-generation investigations, referencing recent circuit-level insights and real-world assay optimization.

16308 records 7/1088 page Previous Next First page 上5页 678910 下5页 Last page